Abstract
Background Several lysosomal genes are associated with Parkinson’s disease (PD), yet the association between PD and ARSA, which encodes for the enzyme arylsulfatase A, remains controversial.
Objectives To evaluate the association between rare ARSA variants and PD.
Methods To study possible association of rare variants (minor allele frequency<0.01) in ARSA with PD, we performed burden analyses in six independent cohorts with a total of 5,801 PD patients and 20,475 controls, using optimized sequence Kernel association test (SKAT-O), followed by a meta-analysis.
Results We found evidence for an association between functional ARSA variants and PD in four independent cohorts (P≤0.05 in each) and in the meta-analysis (P=0.042). We also found an association between loss-of-function variants and PD in the UKBB cohort (P=0.005) and in the meta-analysis (P=0.049). However, despite replicating in four independent cohorts, these results should be interpreted with caution as no association survived correction for multiple comparisons. Additionally, we describe two families with potential co-segregation of the ARSA variant p.E384K and PD.
Conclusions Rare functional and loss-of-function ARSA variants may be associated with PD. Further replication in large case-control cohorts and in familial studies is required to confirm these associations.
Competing Interest Statement
RNA research is funded by the Michael J. Fox Foundation, the Silverstein Foundation and the Parkinson’s Foundation. He received consultation fees from Gain Therapeutics, Takeda and Genzyme/Sanofi. ZGO received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Bial Biotech, Bial, Handl Therapeutics, UCB, Capsida, Denali Lighthouse, Guidepoint and Deerfield. The rest of the authors have nothing to report.
Funding Statement
This study was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The Columbia University cohort is supported by the Parkinson′s Foundation, the National Institutes of Health (K02NS080915 and UL1 TR000040) and the Brookdale Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by McGill university Institutional Review Board (IRB), approval A11-M60-21A.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Relevant conflicts of interest/financial disclosures: RNA research is funded by the Michael J. Fox Foundation, the Silverstein Foundation and the Parkinson’s Foundation. He received consultation fees from Gain Therapeutics, Takeda and Genzyme/Sanofi. ZGO received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Bial Biotech, Bial, Handl Therapeutics, UCB, Capsida, Denali Lighthouse, Guidepoint and Deerfield. The rest of the authors have nothing to report.
Funding: This study was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The Columbia University cohort is supported by the Parkinson’s Foundation, the National Institutes of Health (K02NS080915 and UL1 TR000040) and the Brookdale Foundation.
Data Availability
All data produced in the present work are contained in the manuscript
